Clinical Research Directory

Inclusion Criteria: * Histologically or cytologically confirmed small-cell lung cancer (SCLC) * Limited disease (stage II-III) * Stage I if ineligible for surgery * Eastern Cooperative Oncology Group (ECOG) Performance 0-2 * Measureable disease according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 * Adequate organ function defined as: (a) Serum serum alanine transaminase (ALT) ≤ 3 x upper limit of normal (ULN); (b) Total serum bilirubin ≤ 1.5 x ULN; (c) Absolute neutrophil count (ANC) ≥ 1.5 x 109/L; (d) Platelets ≥ 100 x 109/L; (e) Creatinine \< 100 µmol/L and calculated creatinine-clearance \> 50 ml/min. If calculated creatinine-clearance is \< 50 ml/min, an ethylene diamine tetra-acetic acid (EDTA) clearance should be performed. * Pulmonary function: Forced Expiratory Volume in One Second (FEV1) \> 1 l or 30 % of predicted value and diffusing capacity of the lungs for carbon monoxide (DLCO) \> 30 % of predicted value * All fertile patients should use safe contraception * Written informed consent Exclusion Criteria: * prior systemic therapy for small-cell lung cancer * Previous radiotherapy to the thorax * malignant cells in pericardial or pleural fluid (at least one sample should be analysed if pleural fluid is present * serious concomitant systemic disorders (for example active infection, unstable cardiovascular disease) that in the opinion of the investigator would compromise the patient's ability to complete the study or interfere with the evaluation of the efficacy and safety of the study treatment * conditions - medical, social, psychological - which could prevent adequate information and follow-up * clinically active cancer other than SCLC. Hormonal therapy for prostate cancer or breast cancer and basocellular carcinoma of the skin is allowed * pregnancy, lactation